Swiss Hypertension and Risk Factor Program (SHARP): Cardiovascular risk factors management in patients with type 2 diabetes in Switzerland

References

• Hypertension in Diabetes Study Group. HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11. 309–317
   Google Scholar
• Burt B. L., Whelton P., Roccella E. J., Brown C., Cutler J. A., Higgins M., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313
   PubMed Web of Science ®Google Scholar
• Prescott‐Clarke P., Primatesta P (editors). Health survey for England. 1995. HMSO, London 1997
   Google Scholar
• Harris M. I., Cowie C. C., Stern M. P (editors). Diabetes in America. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, , Washington, DC 1995, 2nd ed
   Google Scholar
• Keane W. F., Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004–1010
   PubMed Web of Science ®Google Scholar
• Groop L., Ekstrand A., Forsblom C., Widen E., Groop P. H., Teppo A. M., Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non‐insulin‐dependent) diabetes mellitus. Diabetologia 1993; 36: 642–647
   PubMed Web of Science ®Google Scholar
• Lebovitz H. E., Wiegmann T. B., Cnaan A., Shahinfar S., Sica D. A., Broadstone V., et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150–155
   PubMedGoogle Scholar
• Chan J. C., Ko G. T., Leung D. H., Cheung R. C., Cheung M. Y., So W. Y., et al. Long‐term effects of angiotensin‐converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590–600
   PubMed Web of Science ®Google Scholar
• Parving H. H., Lehnert H., Brochner‐Mortensen J., Gomis R., Andersen S., Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., et al. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Rickenbach M., Wietlisbach V., Beretta‐Piccoli C., Moccetti T., Gutzwiller F. [Smoking, blood pressure and body weight in the Swiss population: MONICA study. 1988–89]. Schweiz Med Wochenschr Suppl 1993; 48: 21–28
   Google Scholar
• Gutzwiller F., Brenner D. Epidemiology of hypertension in old age. Schweiz Rundsch Med Prax 1991; 80: 684–688
   Google Scholar
• Gutzwiller F., Hoffmann A., Alexander J., Brunner H. R., Schucan C., Vetter W. Epidemiology of blood pressure in 4 Swiss cities. Schweiz Med Wochenschr Suppl 1981; 12: 40–46
   Google Scholar
• Henzen C., Hodel T., Lehmann B., Mosimann T., Horler U., Joss R. Prevalence and therapy of vascular risk factors in hospitalized type 2 diabetic patients. Schweiz Med Wochenschr 2000; 130: 1979–1983
   Google Scholar
• Teuscher A., Egger M., Herman J. B. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch Intern Med 1989; 149: 1942–1945
   PubMedGoogle Scholar
• Burt V. L., Whelton P., Roccella E. J., Brown C., Cutler J. A., Higgins M., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 2203–2204
   Google Scholar
• Conroy R. M., Pyorala K., Fitzgerald A. P., Sans S., Menotti A., De Backer G., et al. SCORE project group. Estimation of the ten‐year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987–1003
   PubMed Web of Science ®Google Scholar
• Cuspidi C., Michev I., Lonati L., Vaccarella A., Cristofari M., Garavelli G., et al. Compliance to hypertension guidelines in clinical practice: A multicentre pilot study in Italy. J Hum Hypertens 2002; 16: 699–703
   PubMed Web of Science ®Google Scholar
• Buhler F. R., de Leche A. S., Schuler G., Gutzwiller F., Baumann F., Schweizer W. [The problem of hypertension in Switzerland. Analysis of a blood pressure study in 21,589 persons]. Schweiz Med Wochenschr 1976; 106: 99–107
   Google Scholar
• Lewis E. J., Hunsiker L. G., Bain R. P., Rohde R. D. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Viberti G., Mogensen C. E., Groop L. C., Pauls J. F. Effect of captopril on progression to clinical proteinuria in patients with insulin‐dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275–279
   PubMed Web of Science ®Google Scholar
• Bruce D. G., Davis W. A., Cull C. A., Davis T. M. Diabetes education and knowledge in patients with type 2 diabetes from the community: The Fremantle Diabetes Study. J Diabetes Complications 2003; 17: 82–89
   PubMed Web of Science ®Google Scholar